Earl, H M <br/><br/>
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials.  [electronic resource] 

 -  British journal of cancer  Oct 2012 
 - 1257-67 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/bjc.2012.370  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibiotics, Antineoplastic--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant<br/>Cyclophosphamide--administration & dosage<br/>Epirubicin--administration & dosage<br/>Female<br/>Fluorouracil--administration & dosage<br/>Follow-Up Studies<br/>Humans<br/>Medication Adherence<br/>Methotrexate--administration & dosage<br/>Middle Aged